Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
$8.22
$8.17
$4.02
$9.15
$376.37M2.82692,487 shsN/A
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
$0.46
$0.43
$0.19
$1.24
$16.71M1.85661,416 shs351,642 shs
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$1.71
+0.6%
$1.81
$1.32
$2.72
$251.19M1.71192,153 shs16,498 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.53
-6.5%
$12.56
$5.22
$27.38
$172.71M0.43155,472 shs56,986 shs
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
$0.86
+4.9%
$0.99
$0.78
$5.15
$28.12M1.57424,487 shs160,882 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
0.00%0.00%0.00%0.00%0.00%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
0.00%+4.27%-3.93%+14.00%-13.64%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%-1.30%+1.17%-12.53%+109.10%
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
0.00%+8.32%-12.09%-14.20%-51.47%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
0.9738 of 5 stars
3.51.00.00.00.60.00.0
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.1794 of 5 stars
3.50.01.72.72.52.51.3
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
4.0827 of 5 stars
3.73.00.04.10.71.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
0.00
N/AN/AN/A
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
0.00
N/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.00
Buy$7.00309.36% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50143.51% Upside
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
3.33
Buy$4.00366.20% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
$74.46M5.05N/AN/A($0.47) per share-17.49
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
$48.34M0.35N/AN/A$0.48 per share0.95
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/A$1.05 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.79$0.80 per share15.56$2.05 per share6.11
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
$101.49M0.29$0.13 per share6.51$1.01 per share0.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
-$57.40M-$1.70N/AN/AN/A-71.11%N/A-42.96%N/A
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
-$23.29M-$1.20N/AN/A-47.03%-113.57%-38.22%N/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.15N/A4.12%34.67%15.24%8/27/2025 (Estimated)
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
-$480KN/A0.00N/AN/A-0.27%-0.90%-0.47%8/14/2025 (Estimated)

Latest IMMP, ADMS, RMTI, LFVN, and CEMI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
-$0.03-$0.04-$0.01-$0.04$17.46 million$18.91 million
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
N/AN/AN/AN/AN/A
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
N/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.44%N/A26.09%3 Years
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
N/AN/AN/AN/AN/A

Latest IMMP, ADMS, RMTI, LFVN, and CEMI Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
21.25
4.53
4.17
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
N/A
1.23
1.04
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A
18.86
N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
0.30
2.95
2.50

Institutional Ownership

CompanyInstitutional Ownership
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
69.97%
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
8.65%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.32%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
23.31%

Insider Ownership

CompanyInsider Ownership
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
18.90%
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
3.30%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.07%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adamas Pharmaceuticals, Inc. stock logo
ADMS
Adamas Pharmaceuticals
13845.79 million37.13 millionOptionable
Chembio Diagnostics, Inc. stock logo
CEMI
Chembio Diagnostics
33736.73 million35.51 millionNot Optionable
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2,021146.04 million141.56 millionOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
30034.17 million32.95 millionOptionable

Recent News About These Companies

Rockwell Medical Inc
Q1 2025 Rockwell Medical Inc Earnings Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adamas Pharmaceuticals stock logo

Adamas Pharmaceuticals NASDAQ:ADMS

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Chembio Diagnostics stock logo

Chembio Diagnostics NASDAQ:CEMI

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

Prima BioMed stock logo

Prima BioMed NASDAQ:IMMP

$1.71 +0.01 (+0.59%)
As of 07/3/2025 03:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.52 -0.88 (-6.53%)
Closing price 07/3/2025 03:34 PM Eastern
Extended Trading
$13.38 +0.86 (+6.83%)
As of 07/3/2025 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Rockwell Medical stock logo

Rockwell Medical NASDAQ:RMTI

$0.86 +0.04 (+4.86%)
As of 07/3/2025 03:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.